Politics

New alarm over China controlling drug supply chains

China is intensifying efforts to control the entire drug supply chain, putting the U.S.

✦ Extractive summary — built from the sources' own reporting•From 1 source•1 min read•Updated November 19, 2026, 10:30 AM UTC
Key points
  • The commission says this can result in a "flywheel effect" that sees royalties and equity in joint ventures flow back to China, fueling new research and infrastructure and attracting global talent.
  • The deals are being made earlier in the drug discovery process, allowing the Chinese partners to gain not just capital but know-how in developing and commercializing treatments.
  • Driving the news: Western drug giants are increasingly entering into licensing agreements with Chinese firms that redirect U.S.

While a chip shortage may result in delays replacing a car or phone, a drug shortage delays treatments for controlling seizures, treating infections or managing severe pain, Brookings Institution senior fellow Marta Wosińska has noted.

This trend should be alarming for policymakers." Threat level: The concern is what happens if China scales up and corners a market, establishing a stranglehold on supplies of key products and ingredients.

Additional details
  • The Western companies see the arrangements as a way to outsource the burden of drug discovery and verify early results.
  • Why it matters: Western drug giants have invested huge sums in Chinese biotechs to boost their product pipelines.
  • "U.S.-China pharma deals are starting to favor the Chinese startups, which risks eroding biotech R&D in the U.S.
  • Between the lines: Drugmakers including AstraZeneca, Bristol Myers Squibb and Pfizer have been drawn by China's surge of investment in the life sciences and the promise of faster clinical trials and product approvals.
  • What they're saying: "The CCP seeks dominance in biotechnology as a source of economic power and geopolitical advantage, and Beijing has spent decades pursuing a deliberate strategy to achieve that at all levels of the value chain," said commission executive director Caitlin Frazer.

How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →

Advertisement

Every article behind this summary — 1 article from 1 outlet